1-3 of 3
Andrew Evens, DO
Close
Sort by
Journal Articles

Patient-Derived Xenografts (PDX) of B Cell Lymphoma in NSG Mice: A Mouse Avatar for Developing Personalized Medicine

Rachel Gerstein, PhD, Zheng Zhou, MD PhD, Hong Zhang, PhD, Andrew Evens, DO, MSc, FACP, Nicole Walsh, PhD, Leonard Shultz, Rita Bortell, PhD, Michael Brehm, PhD, Jan Cerny, MD PhD, Giles Whalen, MD, Jack Leonard, PhD, Bruce Woda, MD, Dale Greiner, PhD, Alan G. Rosmarin, MD
Journal: Blood
Blood (2015) 126 (23): 5408.
https://doi.org/10.1182/blood.V126.23.5408.5408
Published: 2015
Journal Articles

Comparison of Out-of-Pocket Costs for Patients (pts) with Hodgkin’s Disease (HD), Indolent Non-Hodgkin’s Lymphoma (INHL) and Aggressive Non-Hodgkin’s Lymphoma (ANHL).

Kathryn McCaffrey, BA, Matthew Fisher, Lucie Kutikova, PhD, Lee Bowman, PhD, Andrew Evens, DO, Leo Gordon, MD, Heather Auto, Charles Bennett, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2241.
https://doi.org/10.1182/blood.V106.11.2241.2241
Published: 2005
Journal Articles

Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

Brad S. Kahl, MD, Ranjana Advani, MD, Neil Kay, MD, Izidore S. Lossos, MD, Andrew Evens, DO, Leo Gordon, MD, Richard A. Miller, MD, See-Chun Phan, MD
Journal: Blood
Blood (2005) 106 (11): 4758.
https://doi.org/10.1182/blood.V106.11.4758.4758
Published: 2005